search
Back to results

tDCS in Chronic Migraine With Medication Overuse (Edisom) (Edisom)

Primary Purpose

Migraine Disorders, Medication Overuse Headache

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
tDCS
Sponsored by
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine Disorders

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • chronic migraine with medication overuse according to the International Headache Society criteria. Diagnosis was confirmed on the basis of a daily headache diary that all eligible patients filled out in the last month prior to the enrollment. Patients should have failed at least two prophylaxis therapies. Written informed consent.

Exclusion Criteria:

  • known diagnosis of major depression or other major psychiatric disorders identified after psychiatric consultation, cardiac pace maker, clips for previous head surgery, cochlear implant, history of epilepsy, known idiopathic intracranial hypertension, harmful alcohol consumption, pregnancy.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Active Comparator

    Placebo Comparator

    Arm Label

    anodal tDCS

    cathodal tDCS

    sham tDCS

    Arm Description

    anodal tDCS stimulation

    cathodal tDCS stimulation

    sham tDCS stimulation (stopped after 30 seconds)

    Outcomes

    Primary Outcome Measures

    days of headache per month (long-term)
    no. patients with 50% reduction of days of headache per month

    Secondary Outcome Measures

    days of headache per month (mid-term)
    no. patients with 50% reduction of days of headache per month
    analgesic intake per month
    percentage of reduction of analgesic intake per month compared to baseline
    disability
    Migraine Disability Assessment (MIDAS). MIDAS-score 0-:5 low disability 6-10: MILD disability 11-20: Moderate disability more than 2:0 Severe disability.
    catastrophizing attitude
    Pain Catastrophizing Scale (PCS) pathological more than 30 (total score) no cut off for the subscales
    depression
    Beck Depression Inventory (BDI) score more than 7
    state and trait anxiety
    Spielberger questionnaires STAIY1-Y2 ; score between 20-80
    dependence attitude
    Leed questionnaire score Under 10: low dependency 10-22: medium dependency more than 22: high dependency
    allodynia intensity
    Allodynia Symptoms Checklist

    Full Information

    First Posted
    January 4, 2020
    Last Updated
    February 12, 2020
    Sponsor
    Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    Collaborators
    University of Milano Bicocca
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04228809
    Brief Title
    tDCS in Chronic Migraine With Medication Overuse (Edisom)
    Acronym
    Edisom
    Official Title
    Long-term Efficacy of Transcranial Direct Current Stimulation in Chronic Migraine With Medication Overuse: a Phase III, Placebo Controlled, Randomised Clinical Trial (Edisom)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2020
    Overall Recruitment Status
    Completed
    Study Start Date
    December 1, 2015 (Actual)
    Primary Completion Date
    June 30, 2017 (Actual)
    Study Completion Date
    May 30, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    Collaborators
    University of Milano Bicocca

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Transcranial direct current stimulation (tDCS) was suggested to provide beneficial effects in chronic migraine (CM), a condition often associated with medication overuse (MO) for which no long-term therapy is available.
    Detailed Description
    We conducted a randomized controlled trial to assess long-term efficacy of tDCS. Adults diagnosed with CM and MO were assigned to receive in a 1:1:1 ratio anodal, cathodal, or sham tDCS daily for five consecutive days, along with standardized drug withdrawal protocol with intravenous administration of dexamethasone 4 mg and ademetionine 200 mg in saline solution, and oral bromazepam 1.5 mg three times daily. Primary outcome was 50% reduction of days of headache per month at 12 months. Co-secondary outcomes were 50% reduction of days of headache per month at 6 months, reduction of analgesic intake per month, and change in disability and quality of life, catastrophizing, depression, state and trait anxiety, dependence attitude and allodynia intensity. Patients were not allowed to take any migraine prophylaxis drug for the entire study period.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Migraine Disorders, Medication Overuse Headache

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderOutcomes Assessor
    Masking Description
    sham
    Allocation
    Randomized
    Enrollment
    135 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    anodal tDCS
    Arm Type
    Experimental
    Arm Description
    anodal tDCS stimulation
    Arm Title
    cathodal tDCS
    Arm Type
    Active Comparator
    Arm Description
    cathodal tDCS stimulation
    Arm Title
    sham tDCS
    Arm Type
    Placebo Comparator
    Arm Description
    sham tDCS stimulation (stopped after 30 seconds)
    Intervention Type
    Device
    Intervention Name(s)
    tDCS
    Intervention Description
    transcranial direct current stimulation
    Primary Outcome Measure Information:
    Title
    days of headache per month (long-term)
    Description
    no. patients with 50% reduction of days of headache per month
    Time Frame
    12 months
    Secondary Outcome Measure Information:
    Title
    days of headache per month (mid-term)
    Description
    no. patients with 50% reduction of days of headache per month
    Time Frame
    6 months
    Title
    analgesic intake per month
    Description
    percentage of reduction of analgesic intake per month compared to baseline
    Time Frame
    6 and 12 months
    Title
    disability
    Description
    Migraine Disability Assessment (MIDAS). MIDAS-score 0-:5 low disability 6-10: MILD disability 11-20: Moderate disability more than 2:0 Severe disability.
    Time Frame
    6 and 12 months
    Title
    catastrophizing attitude
    Description
    Pain Catastrophizing Scale (PCS) pathological more than 30 (total score) no cut off for the subscales
    Time Frame
    6 and 12 months
    Title
    depression
    Description
    Beck Depression Inventory (BDI) score more than 7
    Time Frame
    6 and 12 months
    Title
    state and trait anxiety
    Description
    Spielberger questionnaires STAIY1-Y2 ; score between 20-80
    Time Frame
    6 and 12 months
    Title
    dependence attitude
    Description
    Leed questionnaire score Under 10: low dependency 10-22: medium dependency more than 22: high dependency
    Time Frame
    6 and 12 months
    Title
    allodynia intensity
    Description
    Allodynia Symptoms Checklist
    Time Frame
    6 and 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: chronic migraine with medication overuse according to the International Headache Society criteria. Diagnosis was confirmed on the basis of a daily headache diary that all eligible patients filled out in the last month prior to the enrollment. Patients should have failed at least two prophylaxis therapies. Written informed consent. Exclusion Criteria: known diagnosis of major depression or other major psychiatric disorders identified after psychiatric consultation, cardiac pace maker, clips for previous head surgery, cochlear implant, history of epilepsy, known idiopathic intracranial hypertension, harmful alcohol consumption, pregnancy.

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    32536270
    Citation
    Grazzi L, Usai S, Bolognini N, Grignani E, Sansone E, Tramacere I, Maravita A, Lauria G. No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial. Cephalalgia. 2020 Oct;40(11):1202-1211. doi: 10.1177/0333102420931050. Epub 2020 Jun 14.
    Results Reference
    derived

    Learn more about this trial

    tDCS in Chronic Migraine With Medication Overuse (Edisom)

    We'll reach out to this number within 24 hrs